Latest news with #DrugDiscovery
CNET
2 days ago
- Health
- CNET
Generative AI Gave MIT Scientists a New Tool to Fight Antibiotic-Resistant Bacteria
Antibiotic-resistant bacteria are dangerous because they already "know" what most antibiotics look like. Scientists at MIT have found a way to create something new: using generative AI to design two antibiotic compounds from scratch that can kill drug-resistant gonorrhea and MRSA in lab dishes and mice. Antibiotic resistance is one of the world's biggest public health threats yet new antibiotics have been scarce for decades. Traditional drug discovery methods rely on screening known chemical libraries -- a slow process with a limited pool of existing molecules to test. In contrast, MIT's AI system generated more than 36 million theoretical compounds, many with chemical structures never seen before, and zeroed in on two standouts. Both are unlike any antibiotic currently in use, offering a glimpse at how AI can move beyond speeding up research to imagine medicines that might have been impossible to find otherwise. "We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way," said Aarti Krishnan, MIT postdoc and one of the study's lead authors. "By venturing into underexplored areas of chemical space, our goal was to uncover novel mechanisms of action." Read also: Do You Really Learn When You Use AI? What MIT Researchers Found How the science was pulled off The MIT team bypassed the limitations of screening existing chemical libraries by asking AI to invent molecules from scratch, generating more than 36 million theoretical compounds, which were then narrowed down to a few to be tested against drug-resistant superbugs. This involved two AI-driven strategies: Fragment-based design: The AI began with a chemical fragment (labeled F1) that showed promise against gonorrhea. It produced millions of derivatives, ultimately refining a shortlist of about 1,000 candidates. Of the 80 chosen by researchers, NG1 emerged as a standout compound that successfully treated drug-resistant gonorrhea in cell cultures and a mouse. Unconstrained generation: The team let the AI roam freely, designing molecules on its own, aiming at MRSA. This produced more than 29 million candidates, which were filtered down to 90 compounds for synthesis. Twenty-two were produced, six performed well in lab tests and one in particular, DN1, proved able to eliminate MRSA skin infections in mice. NG1 and DN1 are structurally distinct from any currently known antibiotics and appear to destroy bacteria by disrupting their cell membranes. NG1 specifically targets LptA, a previously untapped bacterial protein involved in constructing the outer cell membrane. What's next for antibiotic research Phare Bio, a nonprofit in the Antibiotics-AI Project, is refining NG1 and DN1 to improve their drug properties, while researchers expand the AI platform to target other tough pathogens like Mycobacterium tuberculosis (the causative agent of tuberculosis) and Pseudomonas aeruginosa (a group of bacteria that often causes infections in health-care settings). The study, first published in the journal Cell, signals a hopeful turn in the global struggle against superbugs. However, these findings are early-stage. Initial tests and lab results are encouraging, but human safety and efficacy must be established through rigorous lab refinement and clinical trials, a process that could span several years. This effort builds on MIT's previous breakthroughs in AI-guided antibiotic development, including halicin, discovered in 2020 via deep learning, and abaucin, discovered in 2023 via a machine-learning algorithm. Read more: AI Essentials: 29 Ways to Make Gen AI Work for You, According to Our Experts
Yahoo
08-07-2025
- Business
- Yahoo
Advancements in Microplate Reagent Dispensers, Transformation in Genomics, Importance in Drug Discovery & Development, Lab Automation
The Liquid Handling Systems Market is anticipated to grow from USD 4.34 billion in 2024 to USD 6.75 billion by 2030, with a CAGR of 7.64%. Key drivers include the increased focus on lab automation and its role in drug discovery. The pipettes segment leads by product share in 2024, while the manual method segment shows the highest growth. The pharma and biotech sector is the primary end-user, and North America holds the largest regional market share. Major players include Agilent Technologies, Danaher, and Eppendorf. Recent innovations by companies like Hamilton and Eppendorf highlight ongoing advancements in this market. Liquid Handling Systems Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Liquid Handling Systems Market - Focused Insights 2021-2030" report has been added to Liquid Handling Systems Market was valued at USD 4.34 billion in 2024, and is projected to reach USD 6.75 billion by 2030, rising at a CAGR of 7.64% The global liquid handling systems market report consists of exclusive data on 39 vendors. Agilent Technologies, Danaher, Eppendorf, Corning Incorporate, METTLER TOLEDO, Thermo Fisher Scientific, and Tecan Trading AG are some of the leading companies that accounted for the highest market share in the global liquid handling systems market. These vendors offer high-class and advanced liquid handling systems that meet customers' requirements as well as comply with regulatory authorization standards. Major market players are increasing the efficiency of their products and strengthening their market position. These companies have a strong brand image and a wide geographical reach across the global market. Also, the adoption of various strategies, such as product launches, and new product development with advanced technologies and materials and technologies has intensified the competition in the market. The adoption of such strategies by the vendors and their focus on expanding their capabilities have enabled them to gain a higher revenue share in the market. North America is the leading region in the global liquid handling systems market, accounting for around 30% of the total market share. The demand for liquid handling systems is higher in North America compared to other regions, primarily due to the strong presence of numerous biotech and pharmaceutical companies, along with their dedicated research labs and hubs. Additionally, the region is home to many high-tech academic institutions engaged in advanced research, further driving demand for liquid handling solutions. North America hosts a wide range of small, medium, and large market players that actively promote liquid handling equipment, software, and tools for clinical diagnostics, biopharmaceutical R&D, and academic research. Both the U.S. and Canada are witnessing a surge in healthcare R&D activities, significant growth in clinical and research laboratories, and increasing adoption of automation and robotics. Moreover, North America accounts for the highest expenditure on clinical research globally, reinforcing its leadership in the liquid handling systems HANDLING SYSTEMS MARKET TRENDS & DRIVERS Transformation of Liquid Handling Systems in GenomicsThe transformation in liquid handling systems from imprecise and hazardous methods of mouth pipetting in the early 20th century to the introduction of the first air-displacement mechanical pipette in the 1950s significantly revolutionized the genomics field, and now it has become a major field contributing to health revenue for market growth. Furthermore, the development of advanced semi-automated to fully-automated liquid handling systems, tremendously transformed genomics research by offering a higher level of precision, safety, and efficiency that keeps pace with rapid advancements in genomics. According to SPT Labtech (2023), one of the market players stated that advancements in liquid handling systems empower researchers and scientists in the genomic revolution. One of the key technologies that transform genomics is Next-generation Sequencing (NGS), which enables scientists to obtain sequencing data at a lower cost and on a higher scale than ever in Microplate Reagent Dispensers for Liquid Handling SystemsMicroplate reagent Dispensers have become technology-driven tools in liquid handling, enabling precise, automated, and versatile liquid handling for a range of diverse applications in life sciences industries. The growing integration capabilities of robotics and automation systems and the incorporation of technology-driven tools and commands make them one of the most reliable automated tools in liquid handling. There are Several market players advancing microplate reagent dispensing to stand out as unique in the market. For instance, BioTek's range of microplate washers and dispensers can integrate with several robotic systems for increased efficiency and automation. It's one of Multimode Dispenser - BioTEk MultiFlo FX for 6-to 1536-well microplate systems incorporates several unique technologies, such as patented automated media exchange (AMX) modules, random access dispense (RAD), and parallel dispense of Liquid Handling in Drug Discovery & DevelopmentLiquid Handling System is the most essential equipment in several aspects of drug discovery and development (DDD), involved in almost every stage. Increasing attention to liquid handling quality assurance early in the DDD processes is the most recognized way that biopharma companies can enhance efficiency and quality in their regular operations. By incorporating the Liquid Handling Quality Assurance (LHQA) program from compound preparation through clinical studies, biopharma companies' labs can develop quality into their clinical trials processes and decrease the time and cost of drug discovery. As of 2025, more than 40 to 55 drugs are launched annually, and over 10,000 new drug compounds are in the pipeline globally, according to the International Federation of Pharmaceutical Manufacturers and Associations report 2023. The growing clinical studies and increasing demand for liquid handling procedures are accelerating a significant demand for liquid handling Importance of Lab Automation and Automated Liquid Handling SystemsWorldwide, the COVID-19 pandemic significantly influenced the adoption of lab automation and liquid handling automation due to the global shift towards remote work in laboratories. In addition, in the post-pandemic period, the associated benefits, such as significant precision in liquid handling, minimized material wastage, high accuracy, and cost efficiency, are some of the factors that significantly increase attention towards lab automation and automated liquid handling systems. Gilson Incorporated, one of the leading market players in liquid handling systems, reported that the demand and deployment of automated liquid handling systems have significantly accelerated since the start of the COVID-19 pandemic. KEY QUESTIONS ANSWERED Which type of product will dominate the global liquid handling systems market growth? How big is the global liquid handling systems market? What is the projected growth of the global liquid handling systems market? Which region dominates the global liquid handling systems market? What are the factors driving the global liquid handling systems market growth? Who are the major players in the global liquid handling systems market? KEY TAKEAWAYS By Product: In 2024, the pipettes segment accounted for the largest market share of over 28%. By Method: The manual segment shows the highest growth of 8.75% during the forecast period. By Application: The drug discovery & development segment holds the largest market share. By End-User: In 2024, the pharma & biotech companies will dominate the market share. By Geography: North America is the most dominant region for the liquid handling system market, accounting for around 30% of the share. Growth Factor: The global liquid handling systems market is set to grow due to the growing importance of lab automation and automated liquid handling systems and the importance of liquid handling in drug discovery & development. Key Attributes: Report Attribute Details No. of Pages 146 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $4.34 Billion Forecasted Market Value (USD) by 2030 $6.75 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Vendors Agilent Technologies Danaher Eppendorf Corning Incorporate METTLER TOLEDO Thermo Fisher Scientific Tecan Trading AG Other Prominent Vendors Aurora Biomed AUTOGEN BRANDTECH Scientific Bio-Rad Laboratories Borosil Scientific BIOTEC CELLINK CooperSurgical FORMULATRIX Flow Robotics Gilson Incorporate Greiner Bio-One International GmbH HighRes Biosolutions INTEGRA Biosciences HiTec Zang Hudson Lab Automation Hamilton Company Ingersoll Rand Metrohm Molecular Devices Opentrons Orochem Technologies Peak Analysis and Automation Synchron Lab Automation Sartorius SPT Labtech TOMTEC Xi'an Tianlog Science & Technology Co., Ltd Vitrolife Wuhan Bonnin Technology Revvity Waters Corporation SEGMENTATION & FORECASTS By Product Pipettes Automated Liquid Handling Systems Microplate Reagent Dispensers Burettes Others By Method Electronic Automated Manual By Application Drug Discovery & Development Clinical Diagnostics Proteomics & Genomics Others By End-User Pharma & Biotech Companies Academic & Research Labs/Centers Clinical Diagnostic Labs Other End-users By Geography North America US Canada Europe Germany France UK Italy Spain APAC China India Japan South Korea Australia Latin America Brazil Mexico Argentina Middle East & Africa Turkey Saudi Arabia South Africa UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Liquid Handling Systems Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
18-06-2025
- Business
- Globe and Mail
Drug Discovery Platforms Market Projected to Reach USD 512.9 Mn by 2032 with 13.5% CAGR
Drug Discovery Platforms Market, By Drug Type (Small Molecule and Large Molecule), By Technology (Genomics, Proteomics, Cell-Based Assays, High-Throughput Screening, Bioinformatics, Next-Generation Sequencing, Mass Spectrometry, Imaging Technologies, Microfluidics, and Artificial Intelligence & Machine Learning), By Therapeutic Area (Oncology, Neurology, Infectious And Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease) Drug Discovery Platforms Market Insights The drug discovery platforms industry is experiencing robust expansion fueled by technological innovation and rising R&D investments. Experts are leveraging high-throughput screening, AI-driven modeling, and advanced microfluidics to accelerate candidate identification. This blog synthesizes our data-backed market insights, with actual instances from 2024–2025. The Global Drug Discovery Platforms Market size is estimated to be valued at USD 211.3 Mn in 2025 and is expected to reach USD 512.9 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 13.5% from 2025 to 2032. Request Sample Copy of this Report (Use Corporate eMail ID to Get Higher Priority) at: Market Key takeaways: • North America: Leading in AI-integrated screening, driven by biopharma hubs in Boston and San Francisco. • Latin America: Growing collaboration with academic centers in Brazil and Mexico fueling assay development. • Europe: Strong government grants in the UK, Germany, and Switzerland supporting genomics platforms. • Asia Pacific: Rapid CDMO expansion in China and India boosting microfluidics deployments. • Middle East: Investments in precision medicine initiatives across GCC states. • Africa: Emerging research consortia in South Africa adopting cloud-based virtual screening. Market Segmentation: • Platform Type: – High-throughput screening (HTS): Enables 100K+ compound tests/week; used by major pharma. – Virtual screening: AI-driven docking reduced lead time by 20% in 2024 for a European biotech. – Microfluidics: Droplet-based chips processed 1M reactions/month in a 2025 pilot program in Japan. • Technology: – Genomics: NGS-based target validation grew 18% adoption in 2024 for oncology R&D. – Proteomics: Mass-spec arrays identified 500+ biomarkers in 2025 diabetes trials. – Imaging: High-content confocal microscopy expanded throughput by 30% in a US CRO. • End User: – Pharmaceutical & Biotech: Outsourced 65% of initial screening in 2024 to specialized platforms. – Academic Research: Published 150+ discovery papers using integrated platforms last year. – Contract Research Organizations: Launched 12 new service offerings in 2025 for fragment libraries. Growth Factors: • Rising R&D spend: Global pharma R&D climbed to USD 200 Bn in 2024, driving demand for automated assays. • AI and ML integration: Adoption of AI-driven predictive analytics increased by 25% among top 20 biotech firms in 2024. • Personalized medicine push: Over 400 companion diagnostics in pipeline at end-2025, expanding platform scope. • Government grants: A EUR 100 M EU grant in 2024 accelerated genomics-based discovery in academic spin-offs. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: • Consolidation: M&A activity saw 10 platform mergers in 2024, enhancing service portfolios. • Cloud-based workflows: 50% of new platforms in 2025 migrated screening data to secure cloud, improving collaboration. • Fragment-based design: Usage rose to 35% of total screening budgets in 2025 versus 22% in 2023. • Sustainability: Reagent recycling initiatives reduced assay waste by 15% in leading North American labs in 2024. Actionable Insights: • Production Capacity: Over 10 Bn assays capacity in global HTS facilities by 2025—up 18% since 2023. • Pricing Dynamics: Average per-assay cost dropped from USD 3.20 in 2023 to USD 2.75 in 2024, widening market opportunities. • Exports: Asia Pacific platforms exported USD 150 M worth of microfluidic chips in 2024, growing 30% YoY. • Imports: North America imported USD 120 M of high-content imaging modules in 2025, up 22% from 2024. • Use Cases: Oncology screening accounted for 40% of demand, neurology 18%, and infectious disease 12% in 2024. • Nano Indicators: Adoption of droplet microarrays reached 28% penetration in US academic labs by 2025. Key Players: • Thermo Fisher Scientific • Agilent Technologies • Danaher Corporation • PerkinElmer • Merck KGaA • Roche Holding AG • QIAGEN • Bruker Corporation • Bio-Rad Laboratories • Illumina • Charles River Laboratories • Evotec • WuXi AppTec • Schrödinger • Abcam Get Customization on this Report: Competitive Strategies: • Schrödinger's 2024 partnership with a top 10 pharma accelerated lead optimization by 30%, boosting its ROI by 18%. • Illumina's pricing strategy—introducing a tiered subscription for genomic assays—grew recurring revenue by 22% in FY 2024. • Thermo Fisher's acquisition of a microfluidics startup in mid-2025 expanded its market scope, adding USD 50 M in annual revenue. Frequently Asked Questions 1. Who are the dominant players in the Drug Discovery Platforms market? Key players include Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation, PerkinElmer, Merck KGaA, Roche, QIAGEN, Bruker, Bio-Rad, Illumina, Charles River, Evotec, WuXi AppTec, Schrödinger, and Abcam. 2. What will be the size of the Drug Discovery Platforms market in the coming years? The market is projected to grow from USD 211.3 Mn in 2025 to USD 512.9 Mn by 2032 at a CAGR of 13.5%. 3. Which end-users industry has the largest growth opportunity? Pharmaceutical & biotech firms lead demand, followed by academic research and CROs, driven by high-throughput and AI-enabled workflows. 4. How will market development trends evolve over the next five years? Key trends include AI/ML convergence, sustainability in reagent use, cloud-based data management, and fragment-based design. 5. What is the nature of the competitive landscape and challenges in the Drug Discovery Platforms market? Competition centers on technological integration, pricing competitiveness, and partnerships; challenges involve data security, regulatory compliance, and reagent supply constraints. 6. What go-to-market strategies are commonly adopted in the Drug Discovery Platforms market? Strategies include M&A for portfolio expansion, subscription-based assay models, strategic partnerships for co-development, and tiered pricing to penetrate emerging regions. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Yahoo
15-06-2025
- Business
- Yahoo
Goldplat (LON:GDP) Is Investing Its Capital With Increasing Efficiency
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. And in light of that, the trends we're seeing at Goldplat's (LON:GDP) look very promising so lets take a look. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on Goldplat is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.40 = UK£9.4m ÷ (UK£38m - UK£14m) (Based on the trailing twelve months to December 2024). Therefore, Goldplat has an ROCE of 40%. In absolute terms that's a great return and it's even better than the Metals and Mining industry average of 7.0%. Check out our latest analysis for Goldplat Above you can see how the current ROCE for Goldplat compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for Goldplat . Goldplat has not disappointed with their ROCE growth. Looking at the data, we can see that even though capital employed in the business has remained relatively flat, the ROCE generated has risen by 80% over the last five years. Basically the business is generating higher returns from the same amount of capital and that is proof that there are improvements in the company's efficiencies. The company is doing well in that sense, and it's worth investigating what the management team has planned for long term growth prospects. To sum it up, Goldplat is collecting higher returns from the same amount of capital, and that's impressive. Considering the stock has delivered 16% to its stockholders over the last five years, it may be fair to think that investors aren't fully aware of the promising trends yet. So with that in mind, we think the stock deserves further research. One more thing to note, we've identified 2 warning signs with Goldplat and understanding these should be part of your investment process. High returns are a key ingredient to strong performance, so check out our free list ofstocks earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Globe and Mail
04-06-2025
- Business
- Globe and Mail
High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR
"The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others." Browse 363 market data Tables and 31 Figures spread through 358 Pages and in-depth TOC on "High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030 The global High Content Screening Market, valued at US$1.47 billion in 2024, is forecasted to grow at a robust CAGR of 7.5%, reaching US$1.52 billion in 2025 and an impressive US$2.19 billion by 2030. Al and machine learning advancements enhance image analysis capabilities, improving the accuracy and efficiency of high-throughput screening. The expanding applications of HCS in personalized medicine, oncology research, and cell- based assays contribute to market growth. Furthermore, government funding for cell-based research and the rising prevalence of chronic diseases are increasing the adoption of HCS technologies across various research fields. Key segments positively impacting the market include high-content imaging platforms, which dominate due to their critical role in drug discovery and cellular research. Among applications, drug discovery and development lead the market, with pharmaceutical and biotechnology companies being the largest end users due to their extensive R&D investments. The rising adoption of toxicology screening and target identification further supports market growth. Browse in-depth TOC on " High Content Screening Market" 363 - Tables 31 - Figures 358 - Pages By Based on cell detection and analysis system segment, the market is segmented by instrument into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The high content imaging platforms segment dominated the market in 2024. High content imaging platforms hold a significant share in the market owing to their critical role in cellular analysis, drug discovery, and phenotypic screening. These platforms enable high-throughput imaging of live and fixed cells, providing detailed cellular morphology and functional insights necessary for drug screening, toxicity assessment, and disease modelling. By Based on Primary and Secondary screening, the application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The rising focus on precision medicine, personalized therapies, and high-throughput screening applications has reinforced the demand for high content imaging systems in research and clinical settings. By Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest CAGR during the forecast period of 2025-2030. Dominance of the segment is attributable to increasing complexity of drug candidates, particularly in oncology, immunology, and neurological disorders, which has further boosted the demand for HCS in cellular imaging and phenotypic screening. Moreover, the growing trend of precision medicine and biologics development also contributes to the increased utilization of HCS technologies, which is supporting the segment growth in high content screening market. By geography, the high content screening market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to a strong presence of leading academic institutions and market players, substantial investments in biotechnology and pharmaceutical research, and advanced healthcare infrastructure. Asia-Pacific (APAC) is witnessing rapid growth, due to the rising prevalence of chronic diseases, increasing healthcare investments, and expanding research capabilities. Countries like China, India, and Japan are experiencing substantial advancements in biotechnology and drug discovery, supporting to the growing demand for high content screening technologies. Request Sample Pages: The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others. Danaher (US) is one of the leading players in the high content screening market. The company has a presence in more than 60 countries and offers a diversified product portfolio of instruments and software in the high content screening market. Danaher strongly focuses on organic and inorganic growth strategies to maintain a dominant position in the market. The company operates in the market through Beckman Coulter, Molecular Devices, and Integrated DNA Technologies, among others. Danaher's robust global distribution network and dedicated customer support help the company to maintain its dominant position in the market. Revvity, Inc. (US) is one of the dominant players in the high content screening market. The company has a global presence in more than 150 countries and has diversified products for the high content screening market. The company's product offerings include instruments, software, and consumables such as automated cell counter, flow cytometer, microscope, cell imaging systems, and microplate readers. A robust global distribution network and customer-centric approach ensure Revvity serves diverse sectors, including academia, biotechnology, and pharmaceuticals. For more information, Inquire Now!
